Medicare AdvantageCoverageMedium impact
MA08.045p, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection
Independence Blue Cross·Rheumatology, Oncology, Internal Medicine +1 more·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated their policy for tocilizumab and related biosimilars for both intravenous infusion and subcutaneous injection administration. This policy change affects coverage, billing, or authorization requirements for this rheumatoid arthritis and other inflammatory condition medication.
Action Required
By April 1, 2026: Billing team must review the full policy MA08.045p for tocilizumab and related biosimilars to understand updated coverage criteria, prior authorization requirements, and billing guidelines. Update billing protocols and inform providers who prescribe tocilizumab for rheumatoid arthritis, juvenile idiopathic arthritis, and other inflammatory conditions.